Least Burdensome Draft Guidance Would Unduly Increase RCTs - Medtronic
This article was originally published in The Gray Sheet
Executive Summary
FDA's draft guidance on least burdensome premarket requirements likely would increase above current levels the frequency at which randomized controlled trials (RCTs) are required to support premarket approval, leading to "significant over regulation," Medtronic maintains in comments to FDA.